GTGuido Tricot

Guido Tricot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guido Tricot has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Bart Barlogie

    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA

    3 shared publications
  • Athanasios Fassas

    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    2 shared publications
  • Elias Anaissie

    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    2 shared publications
  • Maurizio Zangari

    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    2 shared publications
  • Amir Ahmed Toor

    Harold C. Simmons Cancer Center, University of Texas Southwestern, Dallas, Texas

    1 shared publication
  • Ashraf Badros

    The Myeloma and Transplantation Research Center and the Division of Biometry, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    1 shared publication

Latest Publications

  • The role of cytogenetics in myeloma

    by F Zhan, J Sawyer, G Tricot


  • Open Access

    Treatment advances in multiple myeloma

    by Guido Tricot, Bart Barlogie, Frits Van Rhee


  • Open Access

    Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen

    by Christopher L. Morris, Eric Siegel, Bart Barlogie, Michele Cottler‐Fox, Pei Lin, Athanasios Fassas, Maurizio Zangari, Elias Anaissie, Guido Tricot

    Summary. The mobilization of peripheral blood stem cells was studied in 984 multiple myeloma patients, including 106 patients aged ≥ 70 years. Increasing age correlated inversely with CD34+ yield (P < 0·0001), but also with ≥ 12 months of prior standard chemotherapy (P = 0·0001), < 200 × 109/l platelets (P = 0·0006) premobilization and mobilization with growth factors only (P = 0·0001). After controlling for these age covariates, multivariate analysis identified ≤ 12 months standard therapy and platelet count ≥ 200 × 109/l premobilization as favourable variables (both P < 0·0001), while increasing patient age remained an unfavourable factor (P = 0·0009). With both favourable variables, 85% of elderly patients collected ≥ 4 × 106/kg CD34+ cells in a median of one collection. The effect of age was incremental with no age threshold showing acceleration in the decline of CD34+ yield. Chemotherapy significantly increased CD34+ yield compared with growth factors only. However, the subgroup of patients with > 12 months prior therapy and premobilization platelet count < 200 × 109/l mobilized as many CD34+ cells with granulocyte colony‐stimulating factor (G‐CSF) alone as with chemotherapy and haematopoietic growth factors. Increasing patient age had no effect on post‐transplant neutrophil recovery, but significantly delayed platelet recovery (≥ 50 × 109/l) if < 2 × 106/kg CD34+ cells were infused, but this effect was eliminated completely with infusion of ≥ 4 × 106/kg CD34+ cells. Increasing age adversely affected CD34+ yield even with limited premobilization therapy, indicating that early collection is important in elderly patients.


  • Predicting long‐term (≥ 5 years) event‐free survival in multiple myeloma patients following planned tandem autotransplants

    by Guido Tricot, Trey Spencer, Jeffrey Sawyer, Dan Spoon, Raman Desikan, Athanasios Fassas, Ashraf Badros, Maurizio Zangari, Nikhil Munshi, Elias Anaissie, et al.

    Summary. Although outcome in multiple myeloma (MM) patients has improved significantly with the introduction of autotransplants (AT), the curability of this approach remained to be demonstrated. Therefore, we analysed outcome and prognostic factors using a logistic regression model in 515 consecutive newly diagnosed and previously treated patients intended to receive melphalan‐based tandem transplants with follow up of ≥ 5 years. One quarter ofpatients had event‐free survivals (EFS) ≥ 5 years with no further relapses seen after 7 years (46 patients on plateau). On multivariate analysis, factors associated with EFS ≥ 5 years were absence of chromosome 11 and 13 abnormalities (odds ratio: 6·1), ≤ 12 months of preceding standard‐dose therapy (SDT) (OR: 2·6) and β‐2 microglobulin (B2M) level ≤ 2·5 mg/l at time of first AT (OR: 1·7). Patients with only favourable variables (25%) had a 7‐year EFS in excess of 35%, compared with 15% and 10%, respectively, with one (43%) or two unfavourable variables (27%), and 0% for 5% of patients with three unfavourable variables (P < 0·0001). Using a 1‐year landmark analysis to allow for guaranteed time and thereby excluding early treatment failures, attaining a complete remission (CR) had no significant effect on long‐term survival. Our data are consistent with cure in MM patients with a CR duration ≥ 7 years and re‐establishment of a monoclonal gammopathy of undetermined significance (MGUS) phase in those with persistent evidence of disease post transplantation, but without disease progression ≥ 7 years.